28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Public ClinicalTrials.gov record NCT05358821. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Study identification
- NCT ID
- NCT05358821
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Interventions
- SAGE-718 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 25 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2022
- Primary completion
- Feb 28, 2024
- Completion
- Apr 9, 2024
- Last update posted
- Sep 14, 2025
2022 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sage Investigational Site | Birmingham | Alabama | 35233 | — |
| Sage Investigational Site | Los Alamitos | California | 90720 | — |
| Sage Investigational Site | Englewood | Colorado | 80113 | — |
| Sage Investigational Site | Washington D.C. | District of Columbia | 20057 | — |
| Sage Investigational Site | Boca Raton | Florida | 33431 | — |
| Sage Investigational Site | Tampa | Florida | 33602 | — |
| Sage Investigational Site | Chicago | Illinois | 60612 | — |
| Sage Investigational Site | Baltimore | Maryland | 21218 | — |
| Sage Investigational Site | New York | New York | 10027 | — |
| Sage Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| Sage Investigational Site | Cincinnati | Ohio | 45221 | — |
| Sage Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Sage Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05358821, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05358821 live on ClinicalTrials.gov.